Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.2752W HIGH $30.10
Volume
833.32 K
Value Traded
6.17 M
Short % Float
15.99%
-28.84%Week
-22.46%1 Month
-39.47%3 Month
+16.15%6 Month
-39.85%5 Year
-61.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
332.34 M
EPS (TTM)
-1.13
P/E Ratio
-
Ent. Value
353.21 M
Total Shares
30.50 M
Float Shares
27.07 M
Insiders
11.27%
Institutions
45.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CLPT Catalyst Timeline
Dated clinical, regulatory and corporate events for ClearPoint Neuro Inc.
Past FDA Catalysts and PDUFA Decisions
How CLPT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
ClearPoint Neuro Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CLPT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BURNETT JOSEPHDirector, Officer (CEO and President) | Option | 12,517 130,720 held | $3.47 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CLPT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CLPT for Q2 2026. | ||||
CLPT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CLPT ranks across every disease it competes in
Competitive Position is a premium feature
See how CLPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCLPT News
CLPT▲ +6.4%on this news
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro has announced a 10-year partnership with Sungkyunkwan University to develop focused ultrasound technology for drug delivery. This follows a successful proof-of-concept trial demonstrating the delivery of large molecules across the blood-brain barrier. The collaboration aims to enhance ClearPoint's drug delivery ecosystem and expand its global footprint in neuro navigation and therapy.
Read more →CLPTClearPoint Neuro Reports First Quarter 2026 Results Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth
ClearPoint Neuro reported strong financial growth in the first quarter of 2026, achieving record revenues of $12.1 million, representing a 43% increase year-over-year. The company experienced a 25% organic growth in its devices segment and expansion in its global installed base to over 175 centers. Despite the positive performance, operating expenses rose significantly, reflecting higher costs associated with company growth, while cash reserves decreased compared to the previous quarter. ClearPoint remains optimistic about continued progress across its core growth strategies and achieving future revenue targets.
Read more →CLPTClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro has announced the receipt of a Medical Device License from Health Canada for its Neuro Navigation System. This approval enhances the company's drug delivery ecosystem and allows Canadian neurosurgery centers to utilize their advanced image-guidance workflows. The integration of Canadian clinical trial sites into ClearPoint's global infrastructure aims to streamline processes and support the goal of enabling 20,000 cell and gene therapy procedures annually.
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results Record Revenue and IRRAS Holdings Acquisition Highlight the Company's ‘Fast. Forward.' Strategy
ClearPoint Neuro, Inc. reported a record revenue of $10.4 million in the fourth quarter of 2025, marking a 34% growth compared to the previous year. The successful acquisition of IRRAS Holdings has expanded the company’s portfolio into neurocritical care, enabling access to a new market. Overall revenue for 2025 reached $37.0 million, indicating consistent growth over the past eleven years. The company expects continued expansion, projecting revenues between $52.0 - $56.0 million for 2026, while addressing increased operating expenses resulting from the acquisition and development efforts.
Read more →CLPT▲ +10.3%on this news
ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe
ClearPoint Neuro has received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2, allowing it to offer a unified navigation platform in Europe. This new version enhances surgical capabilities by introducing an intraoperative CT workflow, making precision-guided neurosurgery more accessible. The software aims to reduce operational costs and improve training consistency across global markets.
Read more →CLPTClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million
ClearPoint Neuro, Inc. announced preliminary unaudited revenue growth for Q4 2025, reporting approximately $10.4 million, a 20% increase compared to Q4 2024. The company expects continued expansion in its four growth markets for 2026, projecting total revenues between $54 million and $60 million. The results are preliminary and subject to revision after the annual audit, highlighting potential uncertainties in future performance. ClearPoint is focused on integrating its recent acquisition of the IRRAflow product line, which is expected to contribute to growth.
Read more →CLPTClearPoint Neuro Completes Acquisition of IRRAS Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation
ClearPoint Neuro has successfully completed its acquisition of IRRAS Holdings, enhancing its capabilities in CNS drug delivery. The $5 million cash transaction involved the issuance of shares and outlines a revenue share model on certain sales. With the debut of the IRRAflow technology, ClearPoint aims to strengthen its position in neurocritical care. The merger is viewed as a strategic move to expand market reach and improve patient-centric services.
Read more →CLPT▲ +7.4%on this news
ClearPoint Neuro Announces Agreement to Acquire IRRAS Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.
ClearPoint Neuro has announced an agreement to acquire IRRAS Holdings, which specializes in neurocritical care technologies. This acquisition aims to expand ClearPoint's drug delivery portfolio and gain access to a global market estimated at $0.5 billion for the treatment of intracranial bleeding. The deal is expected to enhance operational scale and includes a cash payment along with shares of ClearPoint common stock. Completion of the merger is contingent upon IRRAS shareholder approval, with expectations of significant revenue growth for 2026.
Read more →CLPT▲ +7.4%on this news
ClearPoint Neuro Reports Third Quarter 2025 Results Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization
ClearPoint Neuro reported its third-quarter financial results for 2025, highlighting a revenue increase of 9% compared to the previous year. The company is enhancing its capabilities with the opening of a new pre-clinical facility and has received FDA clearance for its Laser Therapy System, broadening market access. ClearPoint also announced plans to acquire IRRAS Holdings, which will expand its offerings in neurocritical care. The firm aims to support more cell and gene therapy trials by activating additional specialized treatment centers.
Read more →CLPTClearPoint Neuro Reports Second Quarter 2025 Results Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy
ClearPoint Neuro reported record financial results for the second quarter of 2025, achieving $9.2 million in revenue, which represents a 17% increase compared to the same quarter last year. The company experienced significant growth in neurosurgery navigation and therapy revenue, driven by new product offerings. ClearPoint also secured a substantial cash infusion through a note financing arrangement and a stock purchase agreement, ultimately enhancing its cash reserves to $41.5 million. Despite positive financial results, there was a slight decrease in gross margin and an increase in operating expenses.
Read more →CLPTClearPoint Neuro Reports First Quarter 2025 Results Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products
ClearPoint Neuro, Inc. reported a record revenue of $8.5 million for the first quarter of 2025, marking an 11% increase from the same period in 2024. The company experienced significant growth in its single-use navigation and therapy products, with a notable 70% increase in neurosurgery revenue. Additionally, ClearPoint received FDA clearance for its new software, now available in the market, which is driving revenue and usage growth. Despite increased operating expenses and a decline in cash reserves, the company remains optimistic about its financial outlook for the year.
Read more →CLPTClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35%
ClearPoint Neuro, Inc. reported its fourth quarter and full year 2024 results, achieving record revenue of $31.4 million, marking a 31% growth compared to 2023. The company also noted a significant decrease in operational cash burn by 35%, reflecting improved financial management. Key highlights included the activation of 25 new global centers, further supporting their clinical trials and partnerships. Despite increased operating expenses due to higher personnel costs, ClearPoint remains optimistic about future growth and upcoming product launches. They project continued revenue growth for 2025, estimating between $36 million and $41 million.
Read more →CLPTClearPoint Neuro Reports Third Quarter 2024 Results Achieved Record Revenue and Growth of 41% Operational Cash Burn Reduced to $1.2 Million
ClearPoint Neuro reported impressive financial results for Q3 2024, achieving a record revenue of $8.1 million, representing a 41% increase from the same period last year. The company also reduced its operational cash burn to $1.2 million, a significant 33% decrease year-over-year. Noteworthy advancements include the accelerated growth of its SmartFrame OR platform and PRISM laser therapy systems, contributing to an overall doubling of product revenue. The company remains optimistic, maintaining its full-year revenue outlook of $30 to $33 million.
Read more →CLPTClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024
ClearPoint Neuro, Inc. plans to release its financial results for the third quarter of 2024 on November 7, 2024, after market close. Investors and analysts are invited to participate in a live conference call at 4:30 PM Eastern Time. The company, involved in device, cell, and gene therapy solutions, emphasizes its established regulatory approvals and global operations.
Read more →CLPTClearPoint Neuro Announces Early Repayment of $10 Million Note
ClearPoint Neuro, Inc. has announced the early repayment of a $10 million convertible note to PTC Therapeutics, which was originally set to mature in January 2025. This repayment reflects ClearPoint's confidence in its business and ensures the removal of debt from its balance sheet, thus preventing dilution. The CEO highlighted the ongoing collaboration with PTC Therapeutics, particularly regarding the submission of a Biologics License Application for Upstaza, an investigational treatment currently under FDA review.
Read more →CLPTClearPoint Neuro Reports Second Quarter 2024 Results Second Quarter Revenue Growth +32% Record Revenue Achieved
ClearPoint Neuro reported a remarkable second quarter for 2024, achieving a record revenue of $7.9 million, a 32% increase from the previous year. The product revenue saw significant growth, doubling in some segments and led primarily by the launch of new technologies such as the SmartFrame OR. The company has raised its full-year revenue guidance to between $30.0 and $33.0 million. Despite the challenges of paused collaborations and increased operating expenses, the overall financial health appears strong with reduced cash burn rates.
Read more →CLPTClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024
ClearPoint Neuro, a company specializing in device, cell, and gene therapy technologies, announced it will release its financial results for the second quarter of 2024 on August 7. The company invites investors and analysts to participate in a subsequent conference call, which will also be available for replay. ClearPoint's flagship Neuro Navigation System has received significant regulatory approvals, underscoring its commitment to engaging with the healthcare sector globally. However, the company acknowledges various risks associated with forward-looking statements regarding its future performance and market acceptance.
Read more →CLPT▲ +5.5%on this news
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
ClearPoint Neuro has congratulated its partner Aspen Neuroscience for using its ClearPoint Navigation System in the ASPIRO Phase 1/2a clinical trial. This trial focuses on the safety and tolerability of ANPD001, a regenerative therapy for patients with Parkinson’s Disease. The unique approach involves using the ClearPoint system to navigate and deliver dopaminergic neuron precursor cells directly to the brain. The partnership aims to reduce surgical variability and enhance the efficacy of the treatment across all enrolled patients.
Read more →CLPTClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM 3T Laser Therapy System
ClearPoint Neuro, Inc. has announced the full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery. This launch aims to enhance the accessibility and efficiency of Deep Brain Stimulation (DBS) procedures, which have traditionally been performed in specialized centers. The new technology is expected to allow a larger number of hospitals to conduct DBS, potentially increasing patient treatment rates significantly. Leading neurosurgeons have praised the innovative solutions, indicating a positive impact on clinical practice and patient outcomes.
Read more →CLPTClearPoint Neuro Reports First Quarter 2024 Results First Quarter Revenue Growth +41% Record Revenue Achieved
ClearPoint Neuro reported a record revenue of $7.6 million for the first quarter of 2024, representing a 41% increase year-over-year. Key highlights include a significant rise in biologics and drug delivery revenue, and the activation of a record eight new hospital customers. However, the company also faced challenges, including an 18% decline in revenue from functional neurosurgery navigation and increases in overall operating expenses. The company has reaffirmed its 2024 revenue outlook of $28 million to $32 million.
Read more →About ClearPoint Neuro Inc.
Headquarters120 S. SIERRA AVENUE, SOLANA BEACH, CA, 92075
BIOPHARMAWATCH ELITE PLUS
Trade the next CLPT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime